-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WgXV7SZQ695pQQZcj9oOtDDY151F+aRXxUyvjbaN+oKB5ZFT1QlQ6qlQTRWxDqoi cECMvhC0WOhyOYW45LOfjw== 0000950123-06-003212.txt : 20060315 0000950123-06-003212.hdr.sgml : 20060315 20060315172349 ACCESSION NUMBER: 0000950123-06-003212 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20060315 ITEM INFORMATION: Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20060315 DATE AS OF CHANGE: 20060315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SCHERING PLOUGH CORP CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 06689172 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 9082984000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 8-K 1 y18736e8vk.htm FORM 8-K e8vk
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2006
SCHERING-PLOUGH CORPORATION
(Exact Name of Registrant as Specified in its Charter)
         
New Jersey
(State or Other Jurisdiction of
Incorporation)
  1-6571
(Commission File Number)
  22-1918501
(IRS Employer
Identification Number)
2000 Galloping Hill Road
Kenilworth, NJ 07033
(Address of Principal Executive Office)
Registrant’s telephone number, including area code: (908) 298-4000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


TABLE OF CONTENTS

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
Item 9.01 Financial Statements and Exhibits.
SIGNATURES
Exhibit Index
EX-99.1: PRESS RELEASE


Table of Contents

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
On March 15, 2006 Schering-Plough Corporation announced that Steven H. Koehler will become Vice President and Controller and Schering-Plough’s Principal Accounting Officer effective March 20, 2006.
Mr. Koehler replaces current Vice President, Controller and Principal Accounting Officer, Douglas J. Gingerella, who will become Vice President focusing on the Company’s Value Enhancement Initiative (VEI), effective March 20, 2006.
Mr. Koehler, 55, will join Schering-Plough from The Medicines Company, where he served as Chief Financial Officer and Treasurer since 2002, and Senior Vice President since 2004. From 2002 to 2004, he also served as Corporate Secretary. Prior to The Medicines Company, Mr. Koehler served as Vice President of Finance and Chief Financial Officer of Vion Pharmaceuticals from 2001 to 2002.
Under an agreement with the Company, in the event of a change of control, Mr. Koehler will be provided with compensation and benefits arrangements substantially identical to those included in the form of employment agreement effective upon a change of control filed as Exhibit 10(e)(vi) to the Company’s 10-K for the year ended December 31, 2004.
A press release dated March 15, 2006 related to these appointments is attached as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
     
EXHIBIT NO.   DESCRIPTION
 
   
99.1
  Press Release, dated March 15, 2006, entitled “Schering-Plough Announces Changes in Executive Finance Positions.”

 


Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Schering-Plough Corporation
      
By:   /s/ Susan Ellen Wolf
Susan Ellen Wolf
Corporate Secretary, Vice President, Corporate Governance
and Associate General Counsel
Date: March 15, 2006


Table of Contents

Exhibit Index
     
Exhibit No.   Description
 
   
99.1
  Press Release, dated March 15, 2006, entitled “Schering-Plough Announces Changes in Executive Finance Positions.”

 

EX-99.1 2 y18736exv99w1.htm EX-99.1: PRESS RELEASE exv99w1
 

Exhibit 99.1
     
News Release
   
 
   
Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, New Jersey 07033-0530
   
         
For Release: IMMEDIATELY
  Media Contact:   Denise Foy
 
      (908) 298-7616
 
  Investor Contact:   Alex Kelly
 
      (908) 298-7436
SCHERING-PLOUGH ANNOUNCES CHANGES IN EXECUTIVE FINANCE POSITIONS
KENILWORTH, N.J., March 15, 2006 — Schering-Plough Corporation (NYSE: SGP) today announced several changes among its corporate finance executives.
     Effective March 15, 2006, David A. Piacquad is appointed senior vice president, Business Development. In this role, Piacquad will be responsible for identifying, analyzing and pursuing global business development opportunities in support of the company’s growth and product development objectives. He also has been appointed to the Operations Management Team (OMT). Piacquad succeeds Tom Kelly, who has assumed a new role as vice president, strategic financial projects.
     Effective March 20, 2006, Steven H. Koehler is elected vice president and controller. Koehler joins Schering-Plough from The Medicines Company, where he was most recently senior vice president, chief financial officer and treasurer. From 2002 to 2004, he also served as corporate secretary. In addition, Koehler is appointed as a member of the OMT. He will succeed Douglas Gingerella, who is appointed vice president, focusing on the company’s Value Enhancement Initiative (VEI).
     These positions are based in Kenilworth and report to Robert J. Bertolini, executive vice president and chief financial officer.
     “These changes are designed to further strengthen the global finance team, which continues to play an important role in the transformation of Schering-Plough,” said Fred Hassan, chairman and chief executive officer.
     Prior to joining Schering-Plough, Piacquad held a number of leading operational finance roles across different business units at Johnson & Johnson, most recently as vice president, Ventures and Business Development, a role he assumed in 2004. He also led the business development function for J&J’s over-the-counter drug company, McNeil Consumer Products. In addition, he was CFO for the Ortho Clinical Diagnostics Division and vice president, business development for J&J Corporation.

 


 

     Piacquad holds a B.A. in philosophy from Colgate University, Hamilton, N.Y., and an M.B.A. in Finance from The Wharton School, University of Pennsylvania.
     Prior to his position at The Medicines Company, Koehler was vice president and CFO at Vion Pharmaceuticals. Before that, he served as vice president, Finance Americas for the Knoll Pharmaceuticals Company, the U.S. pharmaceutical unit of BASF. While at BASF, he also spent four years as vice president, global finance and controller, based in Germany. He also held a number of divisional finance lead positions at Baxter International Inc. He began his career in the auditing profession with Arthur Andersen LLP. Koehler holds a B.A from Duke University, Durham, N.C. and an MBA from Northwestern University, Evanston, Ill. He is a Certified Public Accountant.
     Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough’s vision is to earn the trust of the physicians, patients and customers served by its more than 32,000 people around the world.

 

-----END PRIVACY-ENHANCED MESSAGE-----